Answer
Rozanolixizumab reduces serum IgG levels by blocking IgG binding to the neonatal Fc receptor (FcRn), preventing the receptor from protecting IgG against intracellular degradation and recycling it to the cell surface.
Sources for this answer
- Rystiggo 140 mg/ml solution for injectionUCB Pharma Limited · emc · SmPC §5.1 Pharmacodynamic properties · Version 7Document updated
Sources checked